FDA — authorised 14 December 2020
- Marketing authorisation holder: ALMIRALL
- Status: approved
🇺🇸 Klisyri in United States
FDA authorised Klisyri on 14 December 2020
Marketing authorisations
FDA — authorised 14 December 2020
- Application: NDA213189
- Marketing authorisation holder: ALMIRALL
- Local brand name: KLISYRI
- Indication: OINTMENT — TOPICAL
- Status: approved
Klisyri in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is Klisyri approved in United States?
Yes. FDA authorised it on 14 December 2020; FDA authorised it on 14 December 2020.
Who is the marketing authorisation holder for Klisyri in United States?
ALMIRALL holds the US marketing authorisation.